RBC Capital Raises Price Target on Neurocrine Biosciences

On May 29, 2026, RBC Capital raised its price target for Neurocrine Biosciences (NASDAQ:NBIX) to $183 from $180 and maintained an Outperform rating. The firm cited strong Q1 performance but noted potential near-term limitations in Crenessity uptake.

By Jeff Lewis Thu, June 4, 2026 at 7:49 PM GMT+3 2 min read · Yahoo Finance · June 4, 2026, 16:49 UTC

RBC Capital Raises Price Target on Neurocrine Biosciences

Tickers: $NBIX

Topics: Biopharmaceuticals Stock Analysis

Read the full article at Yahoo Finance

More World news

Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC